Infant acute lymphoblastic leukemia with MLL gene rearrangements: Outcome following intensive chemotherapy and hematopoietic stem cell transplantation

Blood

Volumn 104, Issue 12, 2004, Pages 3527-3534

  Kosaka, Yoshiyuki ^b   Koh, Katsuyoshi ^b   Kinukawa, Naoko ^b   Wakazono, Yoshihiro ^b   Isoyama, Keiichi ^b   Oda, Takanori ^b   Hayashi, Yasuhide ^b   Ohta, Shigeru ^b   Moritake, Hiroshi ^b   Oda, Megumi ^b   Nagatoshi, Yoshihisa ^b   Kigasawa, Hisato ^b   Ishida, Yasushi ^b   Ohara, Akira ^b   Hanada, Ryouji ^b   Sako, Masahiro ^b   Sato, Takeyuki ^b   Mizutani, Shuki ^b   Horibe, Keizo ^b   Ishii, Eiichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; TACROLIMUS; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSENSUS; CYTOGENETICS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTERSTITIAL PNEUMONIA; LEUKOCYTE COUNT; LIVER VENOOCCLUSIVE DISEASE; MALE; MULTIVARIATE ANALYSIS; NEWBORN; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 9444269820     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1390     Document Type: Article

References (48)

1. Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol. 1985;3:1513-1521.
2. Crist W, Boyett J, Pullen J, van Eys J, Vietti T. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study. Blood. 1986;67:135-140.
3. Ishii E, Okamura J, Tsuchida M, et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol. 1991;19:28-32.
4. Pui C-H, Kane JR, Crist WM, et al. Biology and treatment of infant leukemia. Leukemia. 1995;9:762-769.
5. Ferster A, Bertrand Y, Benoit Y, et al. Improved survival for acute lymphoblastic leukemia in infancy: the experience of EORTC-Childhood Leukemia Cooperative Group. Br J Haematol. 1994;86:284-290.
6. Reaman GH, Steinherz PG, Gaynon PS, et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep. 1987;71:1033-1038.
7. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209-1217.
8. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol. 1999;17:445-455.
9. Pui C-H, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangement of the 11q23 chromosomal region. Lancet. 2002;359:1909-1915.
10. Pui C-H, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangement. Leukemia. 2003;17:700-706.
11. Emminger W, Emminger-Schmidmeier W, Haas OA, et al. Treatment of infant leukemia with busulfan, cyclophosphamide + etoposide and bone marrow transplantation. Bone Marrow Transplant. 1992;9:313-318.
12. Pirich L, Haut P, Morgan E, et al. Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphoblastic leukemia. Med Pediatr Oncol. 1999;32:1-6.
13. Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. J Clin Oncol. 2000;18:3256-3261.
14. Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of infant acute lymphoblastic leukemia based on early assessment of MLL gene status: results of the Japan Infant Leukemia Study (MLL96). Br J Haematol. 2002;118:999-1010.
15. Borkhardt A, Wuchter C, Viehmann S, et al. Infant acute lymphoblastic leukemia-combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia. 2002;16:1685-1690.
16. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122-3133.
17. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG8497). J Pediatr Hematol Oncol. 1997;19:35-42.
18. Chessells JM, Eden OB, Bailey CC, Lilleyman JS, Richards SM. Acute lymphoblastic leukaemia in infancy: experience in MRC UKLL trials. Leukemia. 1994;8:1275-1279.
19. Nishimura S, Kobayashi M, Ueda K, et al. Treatment of infant acute lymphoblastic leukemia in Japan. Int J Hematol. 1999;69:244-252.
20. Chessells JM, Harrison CJ, Watson SL, et al. Treatment of infants with lymphoblastic leukemia: results of the UK Infant Protocols 1987-1999. Br J Haematol. 2002;117:306-314.
21. Chessells JM, Harrison CJ, Kempski H, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC childhood leukaemia working party. Leukemia. 2002;16:776-784.
22. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia. Cancer. 1997;80:2285-2295.
23. Leung W, Pitts N, Burnette K, et al. Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant. 2001;27:717-722.
24. Kato S, Nishihira H, Kato K, et al. Cord blood transplantation and cord blood bank in Japan. Bone Marrow Transplant. 2000;25:68-70.
25. Nishihira H, Kato K, Isoyama K, et al. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. Br J Haematol. 2003;120:516-522.
26. Isoyama K, Ohnuma K, Kato K, et al. Cord blood transplantation from unrelated donors: a preliminary report from the Japanese cord blood bank network. Leuk Lymphoma. 2003;44:429-438.
27. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med. 2000;342:1846-1854.
28. Grewal SS, Barker JN, Davis SM, et al. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood. 2003;101:4233-4244.
29. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nature. 2003;3:526-532.
30. Frassoni F, Podeata M, Maccario R, et al. Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation. Blood. 2003;102:1138-1141.
31. Okada H, Nomi K, Hamatani S, et al. Induction of graft-versus-host disease and a graft-versus-leukemia effect using ubenimex in a patient with infantile leukemia relapsing after an unrelated cord blood transplant. Bone Marrow Transplant. 2002;30:463-465.
32. Worth LL, Mullen CA, Choroszy M, et al. Treatment of leukemia relapse with recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) following unrelated cord blood transplant: induction of graft-vs-leukemia. Pediatr Tranplant. 2002;6:439-442.
33. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000;25:925-930.
34. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24:386-390.
35. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulfan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130-134.
36. 2 the appropriate dosage of busulfan in pediatric patients undergoing bone marrow transplantation? Blood. 1992;79:2475-2479.
37. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:1013-1018.
38. Cohen A, Rovelli A, Bakker B, et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the working party for late effects-EBMT. Blood. 1999;93:4109-4115.
39. Leung W, Hudson M, Zhu Y, et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14:1185-1190.
40. Giralt S, Estey E, Albitar M, et al. Engraftment of allograft hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4351-4356.
41. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
42. Arnold R, Massenkeli G, Bornhauser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16:2423-2428.
43. Khouri IF, Lee MS, Romaguera J, et al. Allogenic hematopoietic transplantation for mantle-cell lymphoma: molecular remission and evidence of graft-versus-malignancy. Ann Oncol. 1999;10:1293-1299.
44. Tanimoto TE, Kusumi E, Hamaki T, et al. High complete response rate after allogenic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bona Marrow Transplant. 2003;32:131-137.
45. Barker JN, Weisdort DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102:1915-1919.
46. Shibuya A, Kaneko I, Ishii S, Sasaki N. Successful reduced-intensity stem cell transplantation from one-locus HLA-mismatched unrelated cord blood after rejection of unrelated bone marrow in an infant with myelogenous leukemia. Hematology. 2002;7:101-103.
47. Dreyer ZE, Steuber CP, Bowman WP, et al. High risk infant ALL-improved survival with intensive chemotherapy [abstract]. Proc Am Soc Clin Oncol. 1998;17:529a.
48. Cimino G, Ejia L, Cristina R, et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood. 2000;95:96-101.